Member Info for KingHomerJ

Hi Maybe.....I wouldn't stress to much its just general market movements...across the board....all Space stocks seem to take a battering yesterday....

As stated the Fund is the biggest Space fund on earth - i would use any weakness to add more....Results and company presentation tomorrow....with a NAV increase

Forensic……agreed there is significant value in SSIC and similarly in SSIT and the NAV will likely increase significantly each Quarter…..

SSIT is the biggest Space Tech Fund on earth and will likely hit Billions in MC….

Just announced been given a Grant for €28 million by business Finland for satellite R&D

The CLBX is interesting a LOI with Aztraneneca......

PYC have just brought on board Stewart Williams who currently serves as Head of Planning for AstraZeneca's c. $2 billion AXIAL transformation programme....

Huge huge huge potential.... Join the Dots i guess

Mozzz….

Exactly this…the BOD are doing a brilliant Job

HUGE22 May 2026 13:37

As most might know as as i have stated previously

Physiomics has just finished a Trial with Beyond Blood Diagnostics at Blackpool Teaching Hospital for the development of the personal dosing tool.

They will be in the process of evaluating the data as we speak.

Looking onto Beyond Blood Diagnostics there seems to have been some major movements from there side...which clearly has fallen under the radar.

They have signed 2 Major contacts.

one with NATO & one with Nvidia (Yes Nvidia)

NATO

Beyond Blood Diagnostics confirmed a partnership to work with NATO, which includes exploring the deployment of their rapid 15-minute blood cell counting platform in defensive and military field operations. The device, which uses disposable microfluidic cartridges to provide decentralized, lab-quality hematological insights, was integrated into defensive and conflict-zone health resilience scenarios.

Nvidia

Beyond Blood Diagnostics integrated its platform into a joint Lenovo and Nvidia life sciences initiative. The partnership combines Lenovo’s edge computing hardware with Nvidia's specialised AI healthcare architectures. This setup allows Beyond Blood's diagnostic platform to run highly intensive cell-sorting and machine learning algorithms locally on portable hardware, reducing reliance on massive cloud databases during immediate field operations.

There to see on the website as Partners and Collaborators - Right Next to Physiomics

See website https://www.beyondblood.co/

I think it’s safe to say the new BOD putting the building blocks in place that the company very much needed and should be applauded…

More engagement on Socials, More fluent RNS coms, recruiting of a Aztrezeneca Heavy Weight responsible for a £2billion project….

And why wouldn’t they….they are massively invested

Laura - huge - think the highest contract was £175k ever (excluding the £500,000 Merck contract) decades ago….

Huge huge huge news

£345k in a month…..be one of the biggest contract winning months in its history….along side a record year of revenue…..huge huge huge upside here.

As most might know as as i have stated previously

Physiomics has just finished a Trial with Beyond Blood Diagnostics at Blackpool Teaching Hospital for the development of the personal dosing tool.

They will be in the process of evaluating the data as we speak.

Looking onto Beyond Blood Diagnostics there seems to have been some major movements from there side...which clearly has fallen under the radar.

They have signed 2 Major contacts.

one with NATO & one with Nvidia (Yes Nvidia)

NATO

Beyond Blood Diagnostics confirmed a partnership to work with NATO, which includes exploring the deployment of their rapid 15-minute blood cell counting platform in defensive and military field operations. The device, which uses disposable microfluidic cartridges to provide decentralized, lab-quality hematological insights, was integrated into defensive and conflict-zone health resilience scenarios.

Nvidia

Beyond Blood Diagnostics integrated its platform into a joint Lenovo and Nvidia life sciences initiative. The partnership combines Lenovo’s edge computing hardware with Nvidia's specialised AI healthcare architectures. This setup allows Beyond Blood's diagnostic platform to run highly intensive cell-sorting and machine learning algorithms locally on portable hardware, reducing reliance on massive cloud databases during immediate field operations.

There to see on the website as Partners and Collaborators - Right Next to Physiomics

See website https://www.beyondblood.co/

I also note from the article,

"The major factors driving the growth of the biosimulation market include the intensifying global focus on precision medicine, rapid expansion of in-silico drug development, stringent regulatory requirements, and the need to reduce trial costs. Additionally, the rapid expansion of artificial intelligence and machine learning, increasing need for high-performance pharmacokinetic and pharmacodynamic modeling, advanced computational efficiency, and digital transformation initiatives are expected to create significant growth opportunities for players operating in the biosimulation market."

Physomics is a completely different beast to where it was a few years ago.

The addition of bio stats as well as the PD/PK modelling allows PYC to to look at all levels of Trial from early stage proposals to Phase 1/2/3 also across various different fields not just oncology like before - (For example infectious diseases - proven with the contract with GARDP which is funded by the WHO)

There has been company presentations previously which state there is an increasing pipeline and i would anticipate some contracts dropping very very soon, which will again increase the growth the company seems to be running at pace towards.

This doesn't even take into account the Precision doing tool which the trial ended in March/April - I would have thought the company will have the data on this now and its being processed.... This was ran with Beyond Blood Diagnostics and the NHS....... All of which is a huge milestone towards it commercialisation - which if approved could be worth tens of millions when rolled out......And the company already have a means to do this with Dosemrx who has a global precision dosing platform in which we are already integrated into.

The potential returns at this level should be very very very significant and many multiples of its current value

Hits - this exactly…..👍

As we all know they are on every BB.

Let’s just ignore it and not fuel the fire.

It’s that simple…

As any new or potential investor doesn’t want to see BS

Focus on the company’s Facts - potential

That easy really….

Nobody cares about New ID’s or whatever….sad state of people have the time and willingness to do it

Robsaynde….:

OTHER THAN ECR……..

1. Not sure ya have done your due diligence on that one

2. If you had entered ECR at the correct time…. Then you would have made a small fortune bit like KEN.

Victim mentality frankly…blaming other peoples action to justify your own mistakes….

Good luck do what you wish

Let’s just focus on the company and the facts.

Everyone is entitled to an opinion….

Is what it’s is…….back the company or not…..

Frankly the NEW BOD have done more in the last two weeks than the previous in 10 years……..

Research the company - research the he potential and support the BOD’s

It’s that simple- BUY - HOLD or sell if you’re a ain’t happy…..

Trench / Iknow

Trench this statement exactly….as this has company making potential…as well as the increase demand on biostats and the current pipeline and whatever else the NEW BOD see fit with heavy weight expertise.

People whom have never posted on this board are making negative statements…. About the BOD’s - placings blah blah blah.

Have they mentioned the BOD are taking shares as half the salary, have they mentioned the current BOD’s are heavily invested, have they mentioned the BOD have a history of creating shareholder value, have they mentioned anything about the PYC pipeline, expertise, contracts, cash position, potential inflection points (even admitted by the previous BOD)

Let the negative vibes be negative….im sure this won’t effect the positive trajectory of the company

Iknownuffin….

This exactly…..let the company do its thing…..

Is it cheap imo yes - is the potential significant yes imo

As ever people likely be buying much much much higher down the line…as ever

HITS - exactly

When companies starts bringing in senior people with proper heavyweight experience from places like AstraZeneca , it’s rarely just admin reshuffling — it usually means they’re gearing up for something bigger on the commercial and delivery side.

Whether that be huge contracts, precision dosing, biostats are all of the above….i can see this only going in one way…. Huge rerate on the cards

Physiomics plc (AIM: PYC) is showing all the signs of a genuine microcap rerate. After years of being overlooked, the market is finally waking up to the value of its specialist oncology modelling, biometrics expansion, growing contract momentum and refreshed strategic direction. With the share price rebounding strongly from historic lows and investor interest accelerating, this move looks less like a short-term spike and more like the start of a major revaluation story.

A key driver behind the renewed optimism is the energy and fresh perspective brought by the new board. Management have clearly injected renewed focus, ambition and commercial discipline into the company, while also putting significant personal investment into the story themselves. That level of insider commitment creates strong alignment with shareholders and sends a powerful signal that the board genuinely believe the company is materially undervalued.

The recent rise in the share price reflects increasing confidence that Physiomics has been materially undervalued relative to its intellectual property, sector positioning and commercial opportunities. As new contracts land, operational leverage improves and market visibility grows, the upside from these levels could still be substantial.

Importantly, the real blue-sky potential could come from materially larger contract wins and the commercialisation of its Precision Dosing Tool for GCSF. If the company successfully scales adoption of this technology across oncology and pharma partnerships, the valuation opportunity from today’s levels could be huge multiples of the current share price. For many investors, this is no longer just a recovery story — it is increasingly being viewed as a potentially transformational growth story in the making.

AIM investors love discovering recovery growth stories early — and Physiomics is rapidly becoming one of the most talked-about rerate candidates on the market. - Newsnow Wire

Trout,,,,

I think the RNS can actually be read very positively.

The new Board has only just come in, so naturally they are using cautious wording while they complete their review — that’s good governance rather than a red flag.

What stood out to me was that they specifically highlighted the strength of the scientific platform, industry relationships and commercial pipeline, while also stating they believe the company has cash runway into 2027.

The decision for directors to take part of their remuneration in shares also feels like a sign of alignment with shareholders and confidence in the future, especially as it helps preserve cash.

To me, this reads less like a distressed company and more like a new management team trying to tighten operations, improve commercial execution and build a stronger long-term business without overhyping things on day one.